Pakistan · Delayed Price · Currency is PKR Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 14.12 billion. The enterprise value is 16.91 billion.
| Market Cap | 14.12B |
| Enterprise Value | 16.91B |
Important Dates
The next estimated earnings date is Friday, February 26, 2027.
| Earnings Date | Feb 26, 2027 |
| Ex-Dividend Date | Oct 17, 2025 |
Share Statistics
Citi Pharma has 228.46 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 228.46M |
| Shares Outstanding | 228.46M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | -0.33% |
| Owned by Insiders (%) | 50.38% |
| Owned by Institutions (%) | 10.18% |
| Float | 99.56M |
Valuation Ratios
The trailing PE ratio is 16.89.
| PE Ratio | 16.89 |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 18.54 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 20.59 |
| EV / Sales | 1.21 |
| EV / EBITDA | 7.63 |
| EV / EBIT | 8.47 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.30 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.36 |
| Debt / FCF | n/a |
| Interest Coverage | 5.74 |
Financial Efficiency
Return on equity (ROE) is 7.54% and return on invested capital (ROIC) is 8.61%.
| Return on Equity (ROE) | 7.54% |
| Return on Assets (ROA) | 7.09% |
| Return on Invested Capital (ROIC) | 8.61% |
| Return on Capital Employed (ROCE) | 17.60% |
| Weighted Average Cost of Capital (WACC) | 6.74% |
| Revenue Per Employee | 25.95M |
| Profits Per Employee | 1.52M |
| Employee Count | 548 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 3.28 |
Taxes
In the past 12 months, Citi Pharma has paid 599.99 million in taxes.
| Income Tax | 599.99M |
| Effective Tax Rate | 41.80% |
Stock Price Statistics
The stock price has decreased by -24.00% in the last 52 weeks. The beta is 0.45, so Citi Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -24.00% |
| 50-Day Moving Average | 67.89 |
| 200-Day Moving Average | 76.20 |
| Relative Strength Index (RSI) | 48.68 |
| Average Volume (20 Days) | 673,409 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 14.22 billion and earned 835.44 million in profits. Earnings per share was 3.66.
| Revenue | 14.22B |
| Gross Profit | 2.63B |
| Operating Income | 2.03B |
| Pretax Income | 1.44B |
| Net Income | 835.44M |
| EBITDA | 2.23B |
| EBIT | 2.03B |
| Earnings Per Share (EPS) | 3.66 |
Balance Sheet
The company has 274.08 million in cash and 3.07 billion in debt, with a net cash position of -2.79 billion or -12.23 per share.
| Cash & Cash Equivalents | 274.08M |
| Total Debt | 3.07B |
| Net Cash | -2.79B |
| Net Cash Per Share | -12.23 |
| Equity (Book Value) | 11.08B |
| Book Value Per Share | 48.56 |
| Working Capital | 1.93B |
Cash Flow
In the last 12 months, operating cash flow was 777.23 million and capital expenditures -804.66 million, giving a free cash flow of -27.43 million.
| Operating Cash Flow | 777.23M |
| Capital Expenditures | -804.66M |
| Depreciation & Amortization | 199.25M |
| Net Borrowing | 187.71M |
| Free Cash Flow | -27.43M |
| FCF Per Share | -0.12 |
Margins
Gross margin is 18.48%, with operating and profit margins of 14.28% and 5.88%.
| Gross Margin | 18.48% |
| Operating Margin | 14.28% |
| Pretax Margin | 10.09% |
| Profit Margin | 5.88% |
| EBITDA Margin | 15.69% |
| EBIT Margin | 14.28% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 5.66%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 5.66% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 95.79% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.06% |
| Shareholder Yield | 5.61% |
| Earnings Yield | 5.92% |
| FCF Yield | -0.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 18, 2021 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |